Related Experiment Video
Updated: Mar 18, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Hepatitis B: Part II. Updates on Diagnosis and Therapy
Richard Moore Ii1, Claire L Porter2, Jama M Darling3
1Department of Family Medicine at the University of North Carolina, Chapel Hill and North Carolina Department of Health and Human Services, Raleigh.
Hepatitis B management focuses on preventing cirrhosis and liver cancer. Antiviral therapy is recommended for chronic cases with high viral load or cirrhosis, though functional cure remains rare.
Area of Science:
- Hepatology
- Virology
- Gastroenterology
Background:
- Acute hepatitis B presents with jaundice and elevated transaminases, typically resolving spontaneously in adults.
- Chronic hepatitis B is defined by persistent hepatitis B surface antigen for over 6 months.
- Management of chronic hepatitis B aims to prevent cirrhosis, hepatocellular carcinoma, and liver-related mortality.
Purpose of the Study:
- To outline the diagnostic criteria for acute and chronic hepatitis B.
- To detail the evaluation and risk assessment for chronic hepatitis B patients.
- To define therapeutic goals and indications for antiviral treatment.
Main Methods:
- Diagnosis relies on serological markers like hepatitis B surface antigen and antibodies.
- Evaluation includes liver function tests, fibrosis risk assessment, and screening for viral coinfections.
- Treatment decisions are guided by alanine transaminase levels, hepatitis B DNA, and presence of cirrhosis.
Main Results:
- Most acute hepatitis B infections are cleared spontaneously by adults (>95%).
- Oral nucleoside/nucleotide analogues are effective, well-tolerated, and have a high resistance barrier for long-term use.
- Functional cure (loss of hepatitis B surface antigen) is infrequent with current therapies.
Conclusions:
- Antiviral therapy is indicated for chronic hepatitis B with elevated ALT and HBV DNA >2,000 IU/mL, or cirrhosis.
- Prophylactic viral suppression is recommended during immunosuppressive therapy.
- Regular surveillance for hepatocellular carcinoma is crucial for patients with cirrhosis or at high risk.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

